BACKGROUND: Breast cancer is one of the most common diseases affecting women. Inherited susceptibility genes, BRCA1 and BRCA2, are considered in breast, ovarian and other common cancers etiology. BRCA1 and BRCA2 genes have been identified that confer a high degree of breast cancer risk. OBJECTIVE: Our study was performed to identify germline mutations in some exons of BRCA1 and BRCA2 genes for the early detection of presymptomatic breast cancer in females. METHODS: This study was applied on Egyptian healthy females who first degree relatives to those, with or without a family history, infected with breast cancer. Sixty breast cancer patients, derived from 60 families, were selected for molecular genetic testing of BRCA1 and BRCA2 genes. The study also included 120 healthy first degree female relatives of the patients, either sisters and/or daughters, for early detection of presymptomatic breast cancer mutation carriers. Genomic DNA was extracted from peripheral blood lymphocytes of all the studied subjects. Universal primers were used to amplify four regions of the BRCA1 gene (exons 2,8,13 and 22) and one region (exon 9) of BRCA2 gene using specific PCR. The polymerase chain reaction was carried out. Single strand conformation polymorphism assay and heteroduplex analysis were used to screen for mutations in the studied exons. In addition, DNA sequencing of the normal and mutated exons were performed. RESULTS: Mutations in both BRCA1 and BRCA2 genes were detected in 86.7% of the families. Current study indicates that 60% of these families were attributable to BRCA1 mutations, while 26.7% of them were attributable to BRCA2 mutations. Results showed that four mutations were detected in the BRCA1 gene, while one mutation was detected in the BRCA2 gene. Asymptomatic relatives, 80 (67%) out of total 120, were mutation carriers. CONCLUSIONS: BRCA1 and BRCA2 genes mutations are responsible for a significant proportion of breast cancer. BRCA mutations were found in individuals with and without family history.
BACKGROUND:Breast cancer is one of the most common diseases affecting women. Inherited susceptibility genes, BRCA1 and BRCA2, are considered in breast, ovarian and other common cancers etiology. BRCA1 and BRCA2 genes have been identified that confer a high degree of breast cancer risk. OBJECTIVE: Our study was performed to identify germline mutations in some exons of BRCA1 and BRCA2 genes for the early detection of presymptomatic breast cancer in females. METHODS: This study was applied on Egyptian healthy females who first degree relatives to those, with or without a family history, infected with breast cancer. Sixty breast cancerpatients, derived from 60 families, were selected for molecular genetic testing of BRCA1 and BRCA2 genes. The study also included 120 healthy first degree female relatives of the patients, either sisters and/or daughters, for early detection of presymptomatic breast cancer mutation carriers. Genomic DNA was extracted from peripheral blood lymphocytes of all the studied subjects. Universal primers were used to amplify four regions of the BRCA1 gene (exons 2,8,13 and 22) and one region (exon 9) of BRCA2 gene using specific PCR. The polymerase chain reaction was carried out. Single strand conformation polymorphism assay and heteroduplex analysis were used to screen for mutations in the studied exons. In addition, DNA sequencing of the normal and mutated exons were performed. RESULTS: Mutations in both BRCA1 and BRCA2 genes were detected in 86.7% of the families. Current study indicates that 60% of these families were attributable to BRCA1 mutations, while 26.7% of them were attributable to BRCA2 mutations. Results showed that four mutations were detected in the BRCA1 gene, while one mutation was detected in the BRCA2 gene. Asymptomatic relatives, 80 (67%) out of total 120, were mutation carriers. CONCLUSIONS:BRCA1 and BRCA2 genes mutations are responsible for a significant proportion of breast cancer. BRCA mutations were found in individuals with and without family history.
Authors: R B van der Luijt ; P H van Zon ; R P Jansen; C J van der Sijs-Bos ; C C Wárlám-Rodenhuis; M G Ausems Journal: J Med Genet Date: 2001-02 Impact factor: 6.318
Authors: B Górski; T Byrski; T Huzarski; A Jakubowska; J Menkiszak; J Gronwald; A Pluzańska; M Bebenek; L Fischer-Maliszewska; E Grzybowska; S A Narod; J Lubiński Journal: Am J Hum Genet Date: 2000-04-28 Impact factor: 11.025
Authors: Maria Lourdes De Leon Matsuda; Alexander Liede; Elaine Kwan; Cynthia A Mapua; Eva Maria C Cutiongco; Alex Tan; Ake Borg; Steven A Narod Journal: Int J Cancer Date: 2002-04-01 Impact factor: 7.396
Authors: Thomas S Frank; Amie M Deffenbaugh; Julia E Reid; Mark Hulick; Brian E Ward; Beth Lingenfelter; Kathi L Gumpper; Thomas Scholl; Sean V Tavtigian; Dmitry R Pruss; Gregory C Critchfield Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: Tom Walsh; Silvia Casadei; Kathryn Hale Coats; Elizabeth Swisher; Sunday M Stray; Jake Higgins; Kevin C Roach; Jessica Mandell; Ming K Lee; Sona Ciernikova; Lenka Foretova; Pavel Soucek; Mary-Claire King Journal: JAMA Date: 2006-03-22 Impact factor: 56.272
Authors: Alexander Liede; Imtiaz A Malik; Zeba Aziz; Patricia de los Rios Pd; Elaine Kwan; Steven A Narod Journal: Am J Hum Genet Date: 2002-08-13 Impact factor: 11.025
Authors: Nagi S El Saghir; Nathalie K Zgheib; Hussein A Assi; Katia E Khoury; Yannick Bidet; Sara M Jaber; Raghid N Charara; Rania A Farhat; Firas Y Kreidieh; Stephanie Decousus; Pierre Romero; Georges M Nemer; Ziad Salem; Ali Shamseddine; Arafat Tfayli; Jaber Abbas; Faek Jamali; Muhieddine Seoud; Deborah K Armstrong; Yves-Jean Bignon; Nancy Uhrhammer Journal: Oncologist Date: 2015-03-16